Virology & Pathogenesis

Research Leader(s)

Eva Poveda López

BSc Biol, PhD Medical Microbiology
eva.poveda.lopez@sergas.es

986 217 463

Predoctoral Researchers

Alexandre Pérez González

MD
alexandre.perez@iisgaliciasur.es

Helena Codina Márquez

BSc Biol Biotechnology
helena.codina@iisgaliciasur.es

986217463

Technicians

Alejandro Araújo Amejieiras

BScN
alejandro.araujo@iisgaliciasur.es

Lucía Cristina Patiño Álvarez

MSc, Tech Molecular Biology & Epigenetics

External Collaborators

Ana Isabel Mariño Callejo

MD Infectious Diseases

ÁREA SANITARIA FERROL

Antonio Aguilera Guirao

PharmD Microbiology

ÁREA SANITARIA SANTIAGO

Dimitrios Paraskevis

BSc Phys Molecular Epidemiology

National and Kapodistrian University of Athens

Federico García García

PharmD Microbiology

Ibs.GRANADA

George Yendewa

MD, MPH & TM, DrPH (cand) Infectious Diseases

Case Western Reserve University School of Medicine (OH, US)

Hortensia Álvarez Díaz

MD Infectious Diseases

ÁREA SANITARIA FERROL

Michael Freeman

BSc Biol, PhD Molecular Virology & Microbiology

Case Western Reserve University (OH, US)

Michael Lederman

MD Microbiolog, Molecular Biology and Biomedical Ethics

Case Western Reserve University (OH, US)

Nieves Valcarce Pardeiro

BPharm Infectious Diseases

ÁREA SANITARIA FERROL

Nuno S. Osório

BSc Biol Molecular Epidemiology

ICVS, Universidad de Minho, Braga

Sulaiman Lakoh

MB, ChB, MPH, MWACP

Connaught Hospital, Sierra Leona

Human Immunodeficiency Virus (HIV), SARS-CoV-2, COVID-19
Pathogenesis
Molecular epidemiology
Activation / Inflammation
Drug resistance

– Scientific coordination of the COVID19 Cohort of the Galicia Sur Health Research Institute and development of research projects related with the virology and pathogenesis of the SARS-CoV-2 infection.
– Role of extracellular vesicles and mitochondria during viral infections: impact on the pathogenesis of the infection.
– Role of mtDNA on viral infections: impact on the evolution and pathogenesis of the infection.Molecular Epidemiology of HIV infection, including studies of prevalence and characterization of drug resistance.
– Impact of antiretroviral therapy (ART) in residual viremia and in the activation/inflammation levels in the HIV infection.
– HIV Drug Resistance and viral co-infections studies in West Africa.

Virology and Pathogenesis · IIS Galicia Sur

2017

2018

2019

2020

Scientific Papers

Yendewa GA, Lakoh S, Yendewa SA, Bangura K, Lawrence H, Patiño L, Jiba DF, Vandy AO, Murray MJS, Massaquoi SP, Deen GF, Sahr F, Hoffmann CJ, Jacobson JM, Poveda E, Aguilera A, Salata RA. Prevalence of hepatitis B surface antigen and serological markers of other endemic infections in HIV-infected children, adolescents and pregnant women in Sierra Leone: A cross-sectional study. Int J Infect Dis. 2021 Jan;102:45–52. PMID: 33002619. DOI: 10.1016/j.ijid.2020.09.1459. http://www.ncbi.nlm.nih.gov/pubmed/33002619 +Pubmed +DOI

Scientific Papers

Alejos B, Suárez-García I, Rava M, Bautista-Hernández A, Gutierrez F, Dalmau D, Sagastagoitia I, Rivero A, Moreno S, Jarrín I, CoRIS (Eva Poveda; Alexandre Pérez; Manuel Crespo; Luis Morano; Celia Miralles; Antonio Ocampo; Guillermo Pousada). Effectiveness and safety of first-line antiretroviral regimens in clinical practice: a multicentre cohort study. J Antimicrob Chemother. 2020 Oct;75(10):3004–14. PMID: 32667674. DOI: 10.1093/jac/dkaa246. http://www.ncbi.nlm.nih.gov/pubmed/32667674 +Pubmed +DOI
Lakoh S, Jiba DF, Adekanmbi O, Poveda E, Sahr F, Deen GF, Foray LM, Gashau W, Hoffmann CJ, Salata RA, Yendewa GA. Diagnosis and treatment outcomes of adult tuberculosis in an urban setting with high HIV prevalence in Sierra Leone: A retrospective study. Int J Infect Dis. International Society for Infectious Diseases; 2020 Jul;96:112–8. PMID: 32339724. DOI: 10.1016/j.ijid.2020.04.038. https://doi.org/10.1016/j.ijid.2020.04.038 +Pubmed +DOI
Poveda E, Tabernilla A, Fitzgerald W, Salgado-Barreira Á, Grandal M, Pérez A, Mariño A, Álvarez H, Valcarce N, González-García J, Bernardino JI, Gutierrez F, Fujioka H, Crespo M, Ruiz-Mateos E, Margolis L, Lederman MM, Freeman ML, ECRIS integrated in the Spanish AIDS Research Network. Massive release of CD9+ microvesicles in HIV infection, regardless of virologic control. J Infect Dis. 2020 Jun;(E-PUB) PMID: 32603406. DOI: 10.1093/infdis/jiaa375. http://www.ncbi.nlm.nih.gov/pubmed/32603406 +Pubmed +DOI
Ruiz-Mateos E, Poveda E, Lederman MM. Antiretroviral Treatment for HIV Elite Controllers? Pathog Immun. 2020;5(1):121–33. PMID: 32582872. DOI: 10.20411/pai.v5i1.364. http://www.ncbi.nlm.nih.gov/pubmed/32582872 +Pubmed +DOI
Serrano-Villar S, Martínez-Sanz J, Ron R, Talavera-Rodríguez A, Fernández-Felix BM, Herrera S, Muriel A, Fanjul F, Portilla J, Muñoz J, Amador C, de Zárraga MA, Vivancos MJ, Moreno S, Spanish HIV Research Network (CoRIS) (Eva Poveda; Alexandre Pérez; Manuel Crespo; Luis Morano; Celia Miralles; Antonio Ocampo; Guillermo Pousada). Effects of first-line antiretroviral therapy on the CD4/CD8 ratio and CD8 cell counts in CoRIS: a prospective multicentre cohort study. lancet HIV. 2020;7(8):e565–73. PMID: 32763219. DOI: 10.1016/S2352-3018(20)30202-2. http://www.ncbi.nlm.nih.gov/pubmed/32763219 +Pubmed +DOI
Suárez-García I, Alejos B, Delgado E, Rivero M, Pineda JA, Jarrin I, Cohort of the Spanish HIV/AIDS Network (CoRIS) study group (Eva Poveda). How well are we performing the initial assessment of HIV-positive patients? Results from a multicentre cohort in Spain. HIV Med. 2020;21(2):128–34. PMID: 31702111. DOI: 10.1111/hiv.12817. http://www.ncbi.nlm.nih.gov/pubmed/31702111 +Pubmed +DOI
Suárez-García I, Moreno C, Ruiz-Algueró M, Pérez-Elías MJ, Navarro M, Díez Martínez M, Viciana P, Pérez-Martínez L, Górgolas M, Amador C, de Zárraga MA, Jarrín I, Cohort of the Spanish HIV/ADS Research Network (CoRIS) (Eva Poveda; Alexandre Pérez; Manuel Crespo; Luis Morano; Celia Miralles; Antonio Ocampo; Guillermo Pousada). Effectiveness of the combination elvitegravir/cobicistat/tenofovir/emtricitabine (EVG/COB/TFV/FTC) plus darunavir among treatment-experienced patients in clinical practice: a multicentre cohort study. AIDS Res Ther. 2020;17(1):45. PMID: 32690099. DOI: 10.1186/s12981-020-00302-2. http://www.ncbi.nlm.nih.gov/pubmed/32690099 +Pubmed +DOI
Suárez-García I, Ruiz-Algueró M, García Yubero C, Moreno C, Belza MJ, Estébanez M, de Los Santos I, Masiá M, Samperiz Abad G, Muñoz Sánchez J, Omar M, Jarrín I, Cohort of the Spanish HIV/AIDS Research Network (CoRIS) (Eva Poveda; Alexandre Pérez; Manuel Crespo; Luis Morano; Celia Miralles; Antonio Ocampo; Guillermo Pousada). Physicians´ opinions on generic antiretroviral drugs and single-tablet regimen de-simplification for the treatment of HIV infection: a multicentre survey in Spain. J Antimicrob Chemother. 2020;75(2):466–72. PMID: 31665404. DOI: 10.1093/jac/dkz439. http://www.ncbi.nlm.nih.gov/pubmed/31665404 +Pubmed +DOI

Scientific Papers

AIDS Study Group (GeSIDA) of the Spanish Society of Infectious Diseases and Clinical Microbiology and the National AIDS Plan: Executive summary of the GeSIDA/National AIDS Plan consensus document on antiretroviral therapy in adults infected by the human immunodeficiency virus (updated January 2018). Enferm Infecc Microbiol Clin. 2019;37(3):195–202. PMID: 29759422. DOI: 10.1016/j.eimc.2018.02.010. http://www.ncbi.nlm.nih.gov/pubmed/29759422 +Pubmed +DOI
AIDS Study Group (GeSIDA) of the Spanish Society of Infectious Diseases and Clinical Microbiology. Executive summary of the GeSIDA consensus document on control and monitoring of HIV-infected patients. Enferm Infecc Microbiol Clin. 2019 May;37(7):467–75. PMID: 29793873. DOI: 10.1016/j.eimc.2018.03.011. http://www.ncbi.nlm.nih.gov/pubmed/29793873 +Pubmed +DOI
Alvarez M, Casas P, de Salazar A, Chueca N, Guerrero-Beltran C, Rodríguez C, Imaz A, Espinosa N, García-Bujalance S, Pérez-Elías MJ, García-Alvarez M, Iribarren JA, Santos J, Dalmau D, Aguilera A, Vinuesa D, Gutiérrez F, Piérola B, Molina JM, Peraire J, Portilla I, Gómez-Sirvent JL, Olalla J, Galera C, Blanco JR, Riera M, García-Fraile L, Navarro G, Curran A, Poveda E, García F, CoRIS. Surveillance of transmitted drug resistance to integrase inhibitors in Spain: implications for clinical practice. J Antimicrob Chemother. 2019 Jun;74(6):1693–700. PMID: 30838386. DOI: 10.1093/jac/dkz067. http://www.ncbi.nlm.nih.gov/pubmed/30838386 +Pubmed +DOI
Borrajo A, Ranazzi A, Pollicita M, Bellocchi MC, Salpini R, Mauro MV, Ceccherini-Silberstein F, Perno CF, Svicher V, Aquaro S. Different Patterns of HIV-1 Replication in MACROPHAGES is Led by Co-Receptor Usage. Medicina (Kaunas). 2019 Jun;55(6):297. PMID: 31234437. DOI: 10.3390/medicina55060297. http://www.ncbi.nlm.nih.gov/pubmed/31234437 +Pubmed +DOI
Cid-Silva P, Fernández-Bargiela N, Margusino-Framiñán L, Balboa-Barreiro V, Mena-De-Cea Á, López-Calvo S, Vázquez-Rodríguez P, Martín-Herranz I, Míguez-Rey E, Poveda E, Castro-Iglesias Á. Treatment with tenofovir alafenamide fumarate worsens the lipid profile of HIV-infected patients versus treatment with tenofovir disoproxil fumarate, each coformulated with elvitegravir, cobicistat, and emtricitabine. Basic Clin Pharmacol Toxicol. 2019 Apr;124(4):479–90. PMID: 30388308. DOI: 10.1111/bcpt.13161. http://www.ncbi.nlm.nih.gov/pubmed/30388308 +Pubmed +DOI
Cid-Silva P, Margusino-Framiñán L, Balboa-Barreiro V, Pernas-Souto B, Mena-De-Cea Á, Martín-Herranz I, Castro-Iglesias Á, Poveda E. Late HIV Diagnosis but Earlier Antiretroviral Treatment Initiation in Northwest Spain: Impact of Current Treatment Guidelines. J Int Assoc Provid AIDS Care. 2019 Jan;18:232595821882194. PMID: 30798655. DOI: 10.1177/2325958218821940. http://www.ncbi.nlm.nih.gov/pubmed/30798655 +Pubmed +DOI
De Mendoza C, Pirón M, Gonzalez R, Jiménez A, Caballero E, Roc L, Benito R, Ramos JM, Soriano V, HTLV Spanish Study Group (S Pérez; L Morano). Clinical Presentation of Individuals With Human T-Cell Leukemia Virus Type-1 Infection in Spain. Open forum Infect Dis. 2019 Feb;6(2):ofz036. PMID: 30815504. DOI: 10.1093/ofid/ofz036. http://www.ncbi.nlm.nih.gov/pubmed/30815504 +Pubmed +DOI
de Mendoza C, Roc L, Benito R, Reina G, Ramos JM, Gómez C, Aguilera A, Rodríguez-Iglesias M, García-Costa J, Fernández-Alonso M, Soriano V, Spanish HTLV Network (Eva Poveda). HTLV-1 infection in solid organ transplant donors and recipients in Spain. BMC Infect Dis. BMC Infectious Diseases; 2019 Aug;19(1):706. PMID: 31399112. DOI: 10.1186/s12879-019-4346-z. http://www.ncbi.nlm.nih.gov/pubmed/31399112 +Pubmed +DOI
de Mendoza C, Roc L, Fernández-Alonso M, Soriano V, Spanish HTLV Network (Eva Poveda). HTLV testing of solid organ transplant donors. Clin Transplant. 2019;33(10):e13670. PMID: 31321817. DOI: 10.1111/ctr.13670. http://www.ncbi.nlm.nih.gov/pubmed/31321817 +Pubmed +DOI
Lakoh S, Jiba DF, Kanu JE, Poveda E, Salgado-Barreira A, Sahr F, Sesay M, Deen GF, Sesay T, Gashau W, Salata RA, Yendewa GA. Causes of hospitalization and predictors of HIV-associated mortality at the main referral hospital in Sierra Leone: a prospective study. BMC Public Health. BMC Public Health; 2019 Oct;19(1):1320. PMID: 31638941. DOI: 10.1186/s12889-019-7614-3. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6805411/pdf/12889_2019_Article_7614.pdf +Pubmed +DOI
Roc L, de Mendoza C, Fernández-Alonso M, Reina G, Soriano V, Spanish HTLV Network (Eva Poveda). Rapid subacute myelopathy following kidney transplantation from HTLV-1 donors: role of immunosuppresors and failure of antiretrovirals. Ther Adv Infect Dis. 2019;6(6):2049936119868028. PMID: 31467675. DOI: 10.1177/2049936119868028. http://www.ncbi.nlm.nih.gov/pubmed/31467675 +Pubmed +DOI
Yendewa GA, Sahr F, Aguilera A, Lakoh S, Sesay M, Deen GF, Patiño L, Poveda E, Salata RA. Seroprevalence of Hepatitis B, Hepatitis C, and Human T-Cell Lymphotropic Virus Infections in HIV-Infected Patients in Sierra Leone. Am J Trop Med Hyg. 2019 Jun;100(6):1521–4. PMID: 30938283. DOI: 10.4269/ajtmh.18-1001. http://www.ncbi.nlm.nih.gov/pubmed/30938283 +Pubmed +DOI
Yendewa GA, Sahr F, Lakoh S, Ruiz M, Patiño L, Tabernilla A, Deen GF, Sesay M, Salata RA, Poveda E. Prevalence of drug resistance mutations among ART-naive and -experienced HIV-infected patients in Sierra Leone. J Antimicrob Chemother. 2019 Apr;74(7):2024–9. PMID: 30989237. DOI: 10.1093/jac/dkz134. http://www.ncbi.nlm.nih.gov/pubmed/30989237 +Pubmed +DOI

Scientific Papers

AIDS Study Group (GESIDA) of the Spanish Society of Infectious Diseases and Clinical Microbiology and the National AIDS Plan. Executive summary of the GESIDA/National AIDS Plan Consensus Document on Antiretroviral Therapy in Adults Infected by the Human Immunodeficiency Virus (Updated January 2017). Enferm Infecc Microbiol Clin. 2018 Aug;36(7):435–45. PMID: 28579016. DOI: 10.1016/j.eimc.2017.04.001. http://www.ncbi.nlm.nih.gov/pubmed/28579016 +Pubmed +DOI
Cid-Silva P, Margusino-Framiñán L, Balboa-Barreiro V, Martín-Herranz I, Castro-Iglesias Á, Pernas-Souto B, Llibre JM, Poveda E. Initial treatment response among HIV subtype F infected patients who started antiretroviral therapy based on integrase inhibitors. AIDS. 2018 Jan;32(1):121–5. PMID: 29112068. DOI: 10.1097/QAD.0000000000001679. http://www.ncbi.nlm.nih.gov/pubmed/29112068 +Pubmed +DOI
Grandal M, Pernas B, Tabernilla A, Mariño A, Álvarez H, Valcarce N, Mena A, Castro-Iglesias A, Pérez AB, Delgado M, Poveda E. Prevalence of NS5A resistance associated substitutions in patients with hepatitis C virus genotypes 1a and 3: Impact on current therapeutic strategies. J Med Virol. 2018 Jun;90(6):1094–8. PMID: 29427437. DOI: 10.1002/jmv.25048. http://www.ncbi.nlm.nih.gov/pubmed/29427437 +Pubmed +DOI
Lemey P, Stanojevic M, Vandamme A-M. Optimization of the results generated by large-scale sequenc- ing for the study of drug resistance in HIV infection: A system- atic review. International BioInformatics Workshop on Virus Evolution and Molecular Epidemiology. Infect Genet Evol. 2018 Apr;19:335–6. DOI: 10.1016/j.meegid.2013.08.023. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5905554/pdf/vey010.001.pdf +DOI
Poveda E, Crespo M. Hot News: Impact of Low-level Viremia on Treatment Outcomes During ART – Is it Time to Revise the Definition of Virological Failure? AIDS Rev. 2018;20(1):71–2. PMID: 29628513. http://www.ncbi.nlm.nih.gov/pubmed/29628513 +Pubmed
Yendewa GA, Poveda E, Lakoh S, Yendewa SA, Jiba DF, Salgado-Barreira A, Sahr F, Salata RA. High Prevalence of Late-Stage Disease in Newly Diagnosed Human Immunodeficiency Virus Patients in Sierra Leone. Open forum Infect Dis. 2018 Sep;5(9):ofy208. PMID: 30191158. DOI: 10.1093/ofid/ofy208. http://www.ncbi.nlm.nih.gov/pubmed/30191158 +Pubmed +DOI
Yendewa GA, Poveda E, Yendewa SA, Sahr F, Quiñones-Mateu ME, Salata RA. HIV/AIDS in Sierra Leone: Characterizing the Hidden Epidemic. AIDS Rev. 2018 Apr;20(2):104–13. PMID: 29938704. DOI: 10.24875/AIDSRev.M18000022. http://www.ncbi.nlm.nih.gov/pubmed/29938704 +Pubmed +DOI

Scientific Papers

Cid-Silva P, Llibre JM, Fernández-Bargiela N, Margusino-Framiñán L, Balboa-Barreiro V, Pernas-Souto B, Martín-Herranz I, Castro-Iglesias Á, Poveda E. Clinical Experience with the Integrase Inhibitors Dolutegravir and Elvitegravir in HIV-infected Patients: Efficacy, Safety and Tolerance. Basic Clin Pharmacol Toxicol. 2017 Nov;121(5):442–6. PMID: 28627771. DOI: 10.1111/bcpt.12828. IF2017:2.659; Q2. http://www.ncbi.nlm.nih.gov/pubmed/28627771 +Pubmed +DOI
de Mendoza C, Caballero E, Aguilera A, Requena S, de Lejarazu RO, Pirón M, González R, Jiménez A, Roc L, Treviño A, Benito R, Fernández-Alonso M, Aguinaga A, Rodríguez C, García-Costa J, Blanco L, Ramos JM, Calderón E, Eirós JM, Sauleda S, Barreiro P, Soriano V, Spanish HTLV Network (Morano L; Pérez-Castro S; Poveda E). Human T-lymphotropic virus type 1 infection and disease in Spain. AIDS. 2017 Jul;31(12):1653–63. PMID: 28700391. DOI: 10.1097/QAD.0000000000001527. IF2017: 4.914; Q1. http://www.ncbi.nlm.nih.gov/pubmed/28700391 +Pubmed +DOI
Fernández-Caballero JA, Chueca N, Poveda E, García F. Minimizing Next-Generation Sequencing Errors for HIV Drug Resistance Testing. AIDS Rev. 2017;19(4):231–8. PMID: 28534892. IF2017: 2.775; Q2. http://www.ncbi.nlm.nih.gov/pubmed/28534892 +Pubmed
Grandal M, Pernas B, Mariño A, Álvarez H, Tabernilla A, Castro-Iglesias Á, Mena Á, Delgado M, Pértega S, Poveda E. Characterization of chronic HCV infection in Northwest Spain: Impact of the treatment strategic plan of the Spanish National Health Service on HCV cure. J Med Virol. 2017 Jul;89(7):1304–8. PMID: 28079256. DOI: 10.1002/jmv.24766. IF2017: 1.988; Q3. http://www.ncbi.nlm.nih.gov/pubmed/28079256 +Pubmed +DOI
Meijide H, Mena Á, Rodríguez-Osorio I, Castro-Iglesias Á, Poveda E. Cancer Incidence in Persons Living With HIV. Clin Infect Dis. 2017 Feb;64(3):388–9. PMID: 28013260. DOI: 10.1093/cid/ciw759. IF2017: 9.117; D1. http://www.ncbi.nlm.nih.gov/pubmed/28013260 +Pubmed +DOI
Meijide H, Mena Á, Rodríguez-Osorio I, Pértega S, Castro-Iglesias Á, Rodríguez-Martínez G, Pedreira J, Poveda E. Trends in hospital admissions, re-admissions, and in-hospital mortality among HIV-infected patients between 1993 and 2013: Impact of hepatitis C co-infection. Enferm Infecc Microbiol Clin. 2017 Jan;35(1):20–6. PMID: 27609631. DOI: 10.1016/j.eimc.2016.07.012. IF2017: 1.707; Q3. http://www.ncbi.nlm.nih.gov/pubmed/27609631 +Pubmed +DOI
Meijide H, Pértega S, Rodríguez-Osorio I, Castro-Iglesias Á, Baliñas J, Rodríguez-Martínez G, Mena Á, Poveda E. Increased incidence of cancer observed in HIV/hepatitis C virus-coinfected patients versus HIV-monoinfected. AIDS. 2017 May;31(8):1099–107. PMID: 28441174. DOI: 10.1097/QAD.0000000000001448. IF2017: 4.914; Q1. http://www.ncbi.nlm.nih.gov/pubmed/28441174 +Pubmed +DOI
Mena A, Meijide H, Rodríguez-Osorio I, Castro A, Poveda E. Liver-related mortality and hospitalizations attributable to chronic hepatitis C virus coinfection in persons living with HIV. HIV Med. 2017 Oct;18(9):685–9. PMID: 28230318. DOI: 10.1111/hiv.12502. IF2017: 2.932; Q2. http://www.ncbi.nlm.nih.gov/pubmed/28230318 +Pubmed +DOI
Pernas B, Rego-Pérez I, Tabernilla A, Balboa V, Relaño S, Grandal M, Crespo M, Mena Á, Castro-Iglesias Á, Blanco FJ, Poveda E. Plasma mitochondrial DNA levels are inversely associated with HIV-RNA levels and directly with CD4 counts: potential role as a biomarker of HIV replication. J Antimicrob Chemother. 2017 Nov;72(11):3159–62. PMID: 28961892. DOI: 10.1093/jac/dkx272. IF2017: 5.217; D1. http://www.ncbi.nlm.nih.gov/pubmed/28961892 +Pubmed +DOI
Poveda E, Crespo M. When is Early Antiretroviral Therapy Early Enough for HIV Remission? AIDS Rev. 2017 Apr;19(2):113–4. PMID: 28534887. IF2017: 2.775; Q2. http://www.ncbi.nlm.nih.gov/pubmed/28534887 +Pubmed
Poveda E, Freeman ML. Hot News: Exosomes as New Players in HIV Pathogenesis – New Data from the IAS 2017. AIDS Rev. 2017;19(3):173–5. PMID: 29019351. IF2017: 2.775; Q2. http://www.ncbi.nlm.nih.gov/pubmed/29019351 +Pubmed
Poveda E, Hernández-Quero J, Pérez-Elías MJ, Ribas MA, Martínez-Madrid OJ, Flores J, Navarro J, Gutiérrez F, García-Deltoro M, Imaz A, Ocampo A, Artero A, Blanco F, Bernal E, Pasquau J, Mínguez-Gallego C, Pérez N, Aiestaran A, García F, Paredes R, PROTEST study group. Genotypic tropism testing of proviral DNA to guide maraviroc initiation in aviraemic subjects: 48-week analysis of results from the PROTEST study. HIV Med. 2017 Aug;18(7):482–9. PMID: 28035758. DOI: 10.1111/hiv.12479. IF2017: 2.932; Q2. http://www.ncbi.nlm.nih.gov/pubmed/28035758 +Pubmed +DOI
Poveda E, Martin-Gayo E. Similar Immunological Profiles Between Nonprogressing HIV Infection in Children and Nonpathogenic SIV Infection. AIDS Rev. 2017;19(1):54–5. PMID: 28182614. IF2017: 2.775; Q2. http://www.ncbi.nlm.nih.gov/pubmed/28182614 +Pubmed
Poveda E, Puoti M, García-Deltoro M, Pineda JA, Téllez F, Granados R, Morano L, García F, Grupo de Estudio de Hepatitis Víricas (GEHEP). News on Viral Hepatitis in HIV: Update from the 2016 GEHEP Conference. AIDS Rev. 2017 Jan;19(1):47–53. PMID: 28182613. IF2017: 2.775; Q2. http://www.ncbi.nlm.nih.gov/pubmed/28182613 +Pubmed
Rodríguez-Osorio I, Cid P, Morano L, Castro Á, Suárez M, Delgado M, Margusino L, Meijide H, Pernas B, Tabernilla A, Pedreira JD, Mena Á, Poveda E. Real life experience with direct-acting antivirals agents against hepatitis C infection in elderly patients. J Clin Virol. 2017 Mar;88:58–61. PMID: 28183063. DOI: 10.1016/j.jcv.2017.01.003. IF2017: 3.101; Q2. http://www.ncbi.nlm.nih.gov/pubmed/28183063 +Pubmed +DOI
Tabernilla A, Grandal M, Pernas B, Castro-Iglesias A, Rodríguez-Osorio I, Mena A, Delgado M, Cid P, Pedreira JD, Poveda E. Short article: Viral dynamics among hepatitis C virus chronic infected patients during direct-acting antiviral agents therapy: impact for monitoring and optimizing treatment duration. Eur J Gastroenterol Hepatol. 2017 Jul;29(7):781–5. PMID: 28410351. DOI: 10.1097/MEG.0000000000000882. IF2017: 2.014; Q4. http://www.ncbi.nlm.nih.gov/pubmed/28410351 +Pubmed +DOI
Treviño A, Aguilera A, Rodríguez-Iglesias MA, Hernandez A, Benito R, Roc L, Ramos JM, Ortíz de Lejarazu R, Poveda E, Rodríguez C, Del Romero J, Calderon E, García J, Requena S, Soriano V, de Mendoza C. HTLV infection in HCV-antibody positive patients in Spain. AIDS Res Hum Retroviruses. 2017 Mar;33(10):1013–7. PMID: 28269998. DOI: 10.1089/AID.2016.0323. IF2017: 1.935; Q3. http://www.ncbi.nlm.nih.gov/pubmed/28269998 +Pubmed +DOI

Scientific Papers

Pernas B, Grandal M, Pertega S, Cañizares A, Castro-Iglesias Á, Mena Á, Rodriguez-Osorio I, Tabernilla A, Pedreira JD, Poveda E. Any impact of blips and low-level viraemia episodes among HIV-infected patients with sustained virological suppression on ART? J Antimicrob Chemother. 2016 Apr;71(4):1051–5. PMID: 26702924. DOI: 10.1093/jac/dkv433. http://www.ncbi.nlm.nih.gov/pubmed/26702924 +Pubmed +DOI
Pernas B, Grandal M, Tabernilla A, Cid P, Pértega S, Castro-Iglesias Á, Mena Á, Margusino L, Pedreira JD, Poveda E. Long-term clinical experience with darunavir (2007-2015) in a large cohort of HIV-infected patients in Spain. J Med Virol. 2016;88(12):2125–31. PMID: 27218208. DOI: 10.1002/jmv.24585. http://www.ncbi.nlm.nih.gov/pubmed/27218208 +Pubmed +DOI
Poveda E, Crespo M. New Strategies for a Comprehensive Fight Against HIV Infection using Monoclonal Antibody Therapy. AIDS Rev. 2016 Jul;18(3):166. PMID: 27721508. IF2016: 3.195; Q2. http://www.ncbi.nlm.nih.gov/pubmed/27721508 +Pubmed
Poveda E, Tabernilla A. New Insights into HIV-1 Persistence in Sanctuary Sites During Antiretroviral Therapy. AIDS Rev. 2016;18(1):55. PMID: 27028272. http://www.ncbi.nlm.nih.gov/pubmed/27028272 +Pubmed
Tabernilla A, Rego-Pérez I, Grandal M, Pernas B, Pértega S, Delgado M, Mariño A, Álvarez H, Mena A, Rodríguez-Osorio I, Pedreira JD, Blanco FJ, Poveda E. Brief Report: European Mitochondrial Haplogroups Impact on Liver Fibrosis Progression Among HCV and HIV/HCV-Coinfected Patients From Northwest Spain. J Acquir Immune Defic Syndr. 2016;73(2):149–53. PMID: 27258234. DOI: 10.1097/QAI.0000000000001097. http://www.ncbi.nlm.nih.gov/pubmed/27258234 +Pubmed +DOI

Scientific Papers

Meijide H, Mena A, Marcos PJ, Rodriguez-Osorio I, Suárez-Fuentetaja R, Castro A, Poveda E, Pedreira JD. Lung cancer in patients living with HIV infection. AIDS. 2015 Nov;29(17):2363–4. PMID: 26544707. DOI: 10.1097/QAD.0000000000000840. IF2015: 4.407; Q1. http://www.ncbi.nlm.nih.gov/pubmed/26544707 +Pubmed +DOI
Paraskevis D, Kostaki E, Beloukas A, Cañizares A, Aguilera A, Rodríguez J, Grandal M, Pernas B, Castro-Iglesias A, Mena Á, Pedreira JD, Poveda E. Molecular characterization of HIV-1 infection in Northwest Spain (2009-2013): Investigation of the subtype F outbreak. Infect Genet Evol. 2015 Mar;30:96–101. PMID: 25527396. DOI: 10.1016/j.meegid.2014.12.012. http://www.ncbi.nlm.nih.gov/pubmed/25527396 +Pubmed +DOI
Pernas B, Mena A, Cañizares A, Grandal M, Castro-Iglesias A, Pértega S, Pedreira JD, Poveda E. Trends on epidemiological, virological, and clinical features among newly diagnosed HIV-1 persons in Northwest Spain over the last 10 years. J Med Virol. 2015 Aug;87(8):1319–26. PMID: 25777786. DOI: 10.1002/jmv.24185. http://www.ncbi.nlm.nih.gov/pubmed/25777786 +Pubmed +DOI
Poveda E, Wyles D, Morano L, Pineda JA, García F, Grupo de Estudio de Hepatitis Víricas (GEHEP), E P, D W, L M, JA P, F G, GEHEP. News on HIV-HCV coinfection: Update from the 2015 GEHEP conference. AIDS Rev. 2015 Oct;17(4):231–7. PMID: 26616846. IF2015: 2.068; Q3. http://www.ncbi.nlm.nih.gov/pubmed/26616846 +Pubmed
Poveda E. Discovery of a Natural Defense Against HIV With Therapeutic Potential. AIDS Rev. 2015;17(4):238. PMID: 26690492. IF2015: 2.068; Q3. http://www.ncbi.nlm.nih.gov/pubmed/26690492 +Pubmed
Poveda E. HIV tropism shift: new paradigm on cell therapy strategies for HIV cure. AIDS Rev. 2015;17(1):65. PMID: 25608470. IF2015: 2.068; Q3. http://www.ncbi.nlm.nih.gov/pubmed/25608470 +Pubmed
Tabernilla A, Poveda E. The START Trial: Definitive Evidence to Treat All HIV-Positive Persons Regardless of CD4 Counts. AIDS Rev. 2015;17(3):187. PMID: 26450809. IF2015: 2.068; Q3. http://www.ncbi.nlm.nih.gov/pubmed/26450809 +Pubmed
Treviño A, Caballero E, de Mendoza C, Aguilera A, Pirón M, Soriano V, Spanish HIV-2/HTLV Study Group. The Burden of Neglected HIV-2 and HTLV-1 Infections in Spain. AIDS Rev. 2015;17(4):212–9. PMID: 26616845. IF2015: 2.068; Q3. http://www.ncbi.nlm.nih.gov/pubmed/26616845 +Pubmed

Scientific Papers

de Mendoza C, Caballero E, Aguilera A, Pirón M, Ortiz de Lejarazu R, Rodríguez C, Cabezas T, González R, Treviño A, Soriano V, Spanish HIV-2/HTLV Group. HIV-2 and HTLV-1 infections in Spain, a non-endemic region. AIDS Rev. 2014;16(3):152–9. PMID: 25180694. IF2014: 2.775; Q2. http://www.ncbi.nlm.nih.gov/pubmed/25180694 +Pubmed
Garcia F, Poveda E, Pérez-Elías MJ, Quero JH, Ribas MA, Martínez-Madrid OJ, Flores J, Crespo M, Gutiérrez F, García-Deltoro M, Imaz A, Ocampo A, Artero A, Blanco F, Bernal E, Pasquau J, Mínguez-Gallego C, Pérez N, Aiestarán A, Paredes R. Genotypic tropism testing in proviral DNA to guide maraviroc initiation in aviremic subjects: 48-week analysis of the PROTEST study. J Int AIDS Soc. 2014 Jan;17(4 Suppl 3):19520. PMID: 25394029. DOI: 10.7448/ias.17.4.19520. IF: 5.090; Q1. http://www.ncbi.nlm.nih.gov/pubmed/25394029 +Pubmed +DOI
Mena A, Moldes L, Meijide H, Cañizares A, Castro-Iglesias A, Delgado M, Pértega S, Pedreira J, Bou G, Poveda E. Seroprevalence of HCV and HIV infections by year of birth in Spain: impact of US CDC and USPSTF recommendations for HCV and HIV testing. PLoS One. 2014;9(12):e113062. PMID: 25436642. DOI: 10.1371/journal.pone.0113062. IF2014: 3.234; Q1. http://www.ncbi.nlm.nih.gov/pubmed/25436642 +Pubmed +DOI
Mena Á, Pedreira JD, Castro Á, López S, Vázquez P, Poveda E. Metabolic syndrome association with fibrosis development in chronic hepatitis B virus inactive carriers. J Gastroenterol Hepatol. 2014 Jan;29(1):173–8. PMID: 24219115. DOI: 10.1111/jgh.12432. IF2014: 3.504; Q2. http://www.ncbi.nlm.nih.gov/pubmed/24219115 +Pubmed +DOI
Monge S, Guillot V, Alvarez M, Chueca N, Stella N, Peña A, Delgado R, Córdoba J, Aguilera A, Vidal C, García F, CoRIS. Clinically relevant transmitted drug resistance to first line antiretroviral drugs and implications for recommendations. PLoS One. 2014;9(3):e90710. PMID: 24637804. DOI: 10.1371/journal.pone.0090710. IF2014: 3.234; Q1. http://www.ncbi.nlm.nih.gov/pubmed/24637804 +Pubmed +DOI
Pernas B, Grandal M, Mena A, Castro-Iglesias A, Cañizares A, Wyles DL, López-Calvo S, Pértega S, Rodríguez-Osorio I, Pedreira JD, Poveda E. High prevalence of subtype F in newly diagnosed HIV-1 persons in northwest Spain and evidence for impaired treatment response. AIDS. 2014 Jul;28(12):1837–40. PMID: 24871456. DOI: 10.1097/QAD.0000000000000326. IF2014: 2.775; Q2. http://www.ncbi.nlm.nih.gov/pubmed/24871456 +Pubmed +DOI
Poveda E, Pedreira JD. Highlights from CROI 2014 on experimental HIV drugs. AIDS Rev. 2014;16(2):118. PMID: 24984767. IF2014: 2.775; Q2. http://www.ncbi.nlm.nih.gov/pubmed/24984767 +Pubmed
Poveda E, Wyles DL, Mena A, Pedreira JD, Castro-Iglesias A, Cachay E. Update on hepatitis C virus resistance to direct-acting antiviral agents. Antiviral Res. 2014 Aug;108(1):181–91. PMID: 24911972. DOI: 10.1016/j.antiviral.2014.05.015. http://www.ncbi.nlm.nih.gov/pubmed/24911972 +Pubmed +DOI
Poveda E. Ingenol derivates promising for HIV eradication. AIDS Rev. 2014;16(4):246. PMID: 25373349. IF2014: 2.775; Q2. http://www.ncbi.nlm.nih.gov/pubmed/25373349 +Pubmed
Poveda E. Multi-step inhibition against HIV lifecycle-underlying the “magic” of protease inhibitors. AIDS Rev. 2014;16(1):52. PMID: 24589971. IF2014: 2.775; Q2. http://www.ncbi.nlm.nih.gov/pubmed/24589971 +Pubmed
Treviño A, Soriano V, Poveda E, Parra P, Cabezas T, Caballero E, Roc L, Rodríguez C, Eiros JM, Lopez M, De Mendoza C, HIV-2 Spanish Study Group. HIV-2 viral tropism influences CD4+ T cell count regardless of viral load. J Antimicrob Chemother. 2014 Aug;69(8):2191–4. PMID: 24788659. DOI: 10.1093/jac/dku119. IF: 5.313; Q1. http://www.ncbi.nlm.nih.gov/pubmed/24788659 +Pubmed +DOI

Code

CD20/00041

Title

Contrato Sara Borrel

Funder

Instituto de Salud Carlos III

Type

Individual

Duration

2021 – 2023

Eva Poveda López

Code

CM20/00243

Title

Contrato Río Hortega

Funder

Instituto de Salud Carlos III

Type

Individual

Duration

2021 – 2022

Eva Poveda López

Code

IMP/000021

Title

Programa IMPaCT: Medicina Predictiva

Funder

Instituto de Salud Carlos III

Type

Coordinado

Duration

2021 – 2023

Eva Poveda López

Coordinator

Marina Pollán Santamaría (Coord. CIBER de Epidemiología y Salud Pública (CIBERESP))

Code

COV20/00698

Title

Creación de la Cohorte de pacientes COVID19 y muestras asociadas del Instituto de Investigación Sanitaria Galicia Sur (IISGS)

Funder

Instituto de Salud Carlos III

Type

Individual

Duration

2020 – 2021

Eva Poveda López

Code

CT850A-7

Title

SARS-CoV-2.INMOD: Modelo de infección por SARS-CoV-2.

Funder

Axencia Galega de Coñecemento en Saúde (ACIS)

Type

Individual

Duration

2020 – 2021

Benito Regueiro García (External PI)

Cols.

E. Poveda

Code

CT850A-3

Title

SEGUICOVID: Evolución clínica posthospitalización y secuelas pulmonares a medio y largo plazo de la neumonía grave por SARS-CoV-2.

Funder

Axencia de Coñecemento en Saúde (ACIS)

Type

Individual

Duration

2020 – 2021

Alberto Fernández Villar (External PI)

Cols.

A. Pérez

Code

PI19/00747

Title

Papel de las vesículas extracelulares (EVs) y la mitocondria en la activación inmune y la inflamación durante la infección por VIH: impacto del TAR y la supresión viral prolongada.

Funder

Instituto de Salud Carlos III

Type

Multicéntrico

Duration

2020 – 2022

Eva Poveda López

Cols.

A. Mariño. H. Álvarez. L. Patiño

Code

GLD19_0094

Title

Test and Treat Occupational Opportunities (TaTOO)

Funder

GILEAD

Type

Individual

Duration

2019 – 2021

Eva Poveda López

Code

BA18/00034

Title

Impacto de los niveles de ADMmt en plasma en la patogénesis de la infección por VIH. Colaboración con Case Western Reserve University, EE.UU.

Funder

Instituto de Salud Carlos III

Type

Individual

Duration

2019 – 2019

Eva Poveda López

Code

EQC2019-006014-P

Title

Fortalecimiento de la Unidad de Microscopía del IIS Galicia Sur: imagen confocal con super-resolución para estudio de sistemas in vivo.

Funder

Ministerio de Ciencia, Innovación y Universidades / FEDER

Type

Individual

Duration

2019 – 2020

Roberto Carlos Agís Balboa (External PI)

Cols.

E. Poveda

Code

RD16/0025/0026

Title

Red de SIDA de España

Funder

Instituto de Salud Carlos III

Type

Multicéntrico

Duration

2018 – 2021

Eva Poveda López

Coordinator

José Alcamí Pertejo (Coord. )

Code

EQC2018-004581-P

Title

Fortalecimiento e integración de las plataformas de genómica y biología celular mediante técnicas avanzadas de fraccionamiento celular para el análisis de ácidos nucleicos por Digital PCR

Funder

Ministerio de Ciencia, Innovación y Universidades

Type

Individual

Duration

2018 – 2019

Eva Poveda López

Cols.

A. Mariño. G. Yendewa. L. Patiño

Code

PI16/02159

Title

Impacto de las combinaciones terapéuticas actuales frente a la infección por VIH en la viremia residual y marcadores de inflamación/activación: implicaciones en el manejo clínico.

Funder

Instituto de Salud Carlos III

Type

Multicéntrico

Duration

2017 – 2019

Eva Poveda López

Code

IN606A-2016/023

Title

Contrato pre-doctoral – GAIN

Funder

Axencia Galega de Innovación – GAIN

Type

Individual

Duration

2017 – 2019

Eva Poveda López

Code

IN606B-2016/012

Title

Contrato post-doctoral GAIN

Funder

Axencia Galega de Innovación – GAIN

Type

Individual

Duration

2017 – 2019

Eva Poveda López

Code

MV16/00054

Title

Contrato Movilidad Personal Investigador M-AES

Funder

Instituto de Salud Carlos III

Type

Individual

Duration

2017 – 2017

Eva Poveda López

Code

FI14/00557

Title

Contratos predoctorales de formación en Investigación en Salud (PFIS)

Funder

Instituto de Salud Carlos III

Type

Individual

Duration

2015 – 2019

Eva Poveda López

Code

PI13/02266

Title

Plataforma molecular para la caracterización virológica y genética de los pacientes con infección crónica por el virus de la hepatitis C: optimización de la terapia y curación

Funder

Instituto de Salud Carlos III

Type

Multicéntrico

Duration

2014 – 2018

Eva Poveda López

Code

C4671005

Alexandre Pérez González

Title

AN INTERVENTIONAL EFFICACY AND SAFETY, PHASE 2/3, DOUBLE-BLIND, 2-ARM STUDY TO INVESTIGATE ORALLY ADMINISTERED PF 07321332/RITONAVIR COMPARED WITH PLACEBO IN NONHOSPITALIZED SYMPTOMATIC ADULT PARTICIPANTS WITH COVID-19 WHO ARE AT INCREASED RISK OF PROGRESSING TO SEVERE ILLNESS

Start date

2021

Sponsor

PFIZER, S.L.U.

Code

C4671002

Alexandre Pérez González

Title

AN INTERVENTIONAL EFFICACY AND SAFETY, PHASE 2/3, DOUBLE-BLIND, 2-ARM STUDY TO INVESTIGATE ORALLY ADMINISTERED PF-07321332/RITONAVIR COMPARED WITH PLACEBO IN NONHOSPITALIZED SYMPTOMATIC ADULT PARTICIPANTS WITH COVID-19 WHO ARE AT LOW RISK OF PROGRESSING TO SEVERE ILLNESS

Start date

2021

Sponsor

Pfizer Ltd

Code

C4671006

Alexandre Pérez González

Title

Estudio de fase II/III, aleatorizado, doble ciego, con doble simulación y controlado con placebo para evaluar la seguridad y eficacia de 2 pautas de PF-07321332/Ritonavir administrados oralmente para prevenir los síntomas de la infección por SARS-COV-2 en adultos que hayan tenido contacto doméstico con una persona con covid-19 sintomática

Start date

2021

Sponsor

PFIZER, S.L.U.

Title

Caracterización epidemiologica y virológica en pacientes con infección crónica por el virus de la Hepatitis C: impacto en el tratamiento con antivirales de acción directa

URL

https://www.educacion.gob.es/teseo/mostrarRef.do?ref=1825962

Author

Marta Grandal Fustes

Supervisor

Eva Poveda López

External supervisor(s)/co-supervisor(s)

José Domingo Pedreira Andrade

University

Universidade de A Coruña

Date

11/11/2019

Title

Inhibidores de la integrasa: eficacia y seguridad en el tratamiento de pacientes con infección por VIH

URL

https://www.educacion.gob.es/teseo/mostrarRef.do?ref=1782045

Author

Purificación Cid Silva

Supervisor

Eva Poveda López

External supervisor(s)/co-supervisor(s)

Mª Ángeles Castro-Iglesias

University

Universidad de A Coruña

Date

07/06/2019

Title

Infección por el Virus de la Hepatitis C en la era de los antivirales de acción directa: optimización del diagnóstico, tratamiento y progresión de la enfermedad

URL

https://www.educacion.gob.es/teseo/mostrarRef.do?ref=1782324

Author

Andrés Tabernilla García

Supervisor

Eva Poveda López

External supervisor(s)/co-supervisor(s)

Mª Ángeles Castro Iglesias

University

Universidad de A Coruña

Date

06/06/2019

Title

Impacto del virus de la hepatitis C en la evolución de las comorbilidades en pacientes infectados por el VIH (1993-2014).

URL

https://www.educacion.gob.es/teseo/mostrarRef.do?ref=1556259

Author

Héctor Meijide Míguez

Supervisor

Eva Poveda López

University

Universidad de A Coruña

Date

23/11/2017

Title

Caracterización epidemiológica, clínica y virológica de los nuevos diagnósticos de infección por el VIH-1 (2004-2015): impacto en la respuesta al tratamiento antiretroviral

URL

https://www.educacion.gob.es/teseo/mostrarRef.do?ref=1317051

Author

Berta Pernas Souto

Supervisor

Eva Poveda López

University

Universidad de A Coruña

Date

04/10/2016

Title

Resistencia a los nuevos antivirales frente al virus de la hepatitis C